Navigation Links
First identification of a strong oral carcinogen in smokeless tobacco
Date:8/22/2012

PHILADELPHIA, Aug. 22, 2012 Scientists today reported identification of the first substance in smokeless tobacco that is a strong oral carcinogen ― a health risk for the 9 million users of chewing tobacco, snuff and related products in the U.S. ― and called upon the federal government to regulate or ban the substance.

The researchers reported here at the 244th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society. The meeting, which continues through Thursday, features more than 8,600 reports on new developments in science, with an anticipated attendance of 14,000 scientists and others.

"This is the first example of a strong oral cavity carcinogen that's in smokeless tobacco," said Stephen Hecht, Ph.D., who led the study. "Our results are very important in regard to the growing use of smokeless tobacco in the world, especially among younger people who think it is a safer form of tobacco than cigarettes. We now have the identity of the only known strong oral carcinogen in these products."

Evidence has been accumulating for years that people who use smokeless tobacco have an increased risk of cancer of the mouth, esophagus and pancreas. Scientists also knew that smokeless tobacco users are exposed to a variety of carcinogens and experience some damage to their genetic material impairing its normal function. But until now, no substance in these products was clearly implicated as a cause of mouth cancer, explained Hecht, who is at the University of Minnesota.

Hecht's team identified the culprit as (S)-NNN, one of a family of hundreds of compounds called nitrosamines, most of which are carcinogenic, capable of causing cancer. Nitrosamines occur in a variety of foods, ranging from beer to bacon, and also form naturally in the stomach when people eat foods containing high levels of nitrite. But nitrosamine levels in smokeless tobacco are far higher than in food.

To do it, they gave laboratory rats a low dose of two forms of NNN, suspected carcinogens in smokeless tobacco, for 17 months in doses roughly equivalent to a person consuming half of a tin of smokeless tobacco every day for 30 years. One substance, (S)-NNN, induced large numbers of oral and esophageal tumors in the rats.

"The most popular brands of smokeless tobacco that are sold in the U.S. have unacceptably high levels of this particular carcinogen," explained Hecht. "And smokeless tobacco is a known cause of oral cancer. Obviously, we need to decrease the levels of this material in all smokeless tobacco products or eliminate it altogether." Hecht adds that removing (S)-NNN from these products is feasible. In fact, some products on store shelves today have reduced levels of the carcinogen.

Hecht explained that the U.S. Food and Drug Administration has the authority to regulate tobacco products, but no regulations on the levels of specific carcinogens exist yet. "My suggestion is that levels of (S)-NNN in smokeless tobacco be decreased to below 10 parts per billion. That would make it more consistent with the levels of nitrosamines in food products," he said. (S)-NNN also is in cigarettes and other smoked tobacco items, and he suggested that the substance be regulated in these products, as well.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6042

Michael Woods
m_woods@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6293
American Chemical Society


Source:Eurekalert

Related medicine news :

1. IHME professor named first health measurement winner of prestigious innovation award
2. FDA Gives Nod to First Drug for Diabetic Eye Disease
3. Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas
4. Women and Children First? Not So, Says Study
5. WPI to host international workshop focused on technology solutions for first responders
6. First Huntingtons disease center established in Washington, D.C., area
7. Study Gives First Evidence That Adult Human Lungs Can Regrow
8. Hookah smoking increasingly common among first-year college women
9. Sohn Conference and Damon Runyon Cancer Research Foundations name first pediatric research fellows
10. Scientists first to see trafficking of immune cells in beating heart
11. First-of-its-kind approach nanomedicine design effectively targets cancer with decreased toxicity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Mother Nature isn’t the only mom ... fruits and vegetables. , Celebrate these women with more than just a bouquet ... with these five garden-themed options. , Vibrant, Edible, Compact Plants from BrazelBerries: , ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... to identify, fund and implement ideas aimed at improving care and reducing readmission ... “Part of our vision for Trinity Health is to drive innovation that transforms ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and Vancouver, WA, has announced the latest beneficiary of their ongoing community ... and their Mammography Program, which provides free mammograms and diagnostic breast care ...
(Date:5/4/2016)... ... May 04, 2016 , ... The ... research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against ... on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due in ... Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered an ... 2009. , “I’m excited for our eighth summer here in San Diego,” says ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)...  It,s time for an upgrade. There are many medical recorders on the market ... the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned ... manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... BRIDGEWATER, New Jersey , May 4, 2016 /PRNewswire/ ... today its successful completion of an alternative public offering ... its wholly owned operating company, Valeritas, Inc. and a ... unregistered common stock at $5.00 per share. ... completed on May 3, 2016, Valeritas Holdings, Inc. will ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
Breaking Medicine Technology: